免疫原性
病毒学
中和抗体
信使核糖核酸
病毒
免疫系统
脂质体
抗体
大流行
2019年冠状病毒病(COVID-19)
生物
医学
免疫学
疾病
传染病(医学专业)
基因
遗传学
病理
生物化学
作者
Hai Huang,Caili Zhang,Shuping Yang,Wen Xiao,Qian Zheng,Xiangrong Song
标识
DOI:10.1016/j.jconrel.2021.05.024
摘要
COVID-19 pandemic has resulted in an unprecedented global public health crisis. It is obvious that SARS-CoV-2 vaccine is needed to control the global COVID-19 public health crisis. Since obvious advantages including fast manufacturing speed, potent immunogenicity and good safety profile, six mRNA vaccines have been used to prevent SARS-CoV-2 infections in clinic with lipid nanoparticles (LNP) formulation via intramuscular injection. In this work, we first constructed RBD-encoding mRNA (RBD-mRNA) formulated in liposomes (LPX/RBD-mRNA) and investigated the influence of administration routes on the immunogenicity. LPX/RBD-mRNA can express RBD in vivo and successfully induced SARS-CoV-2 RBD specific antibodies in the vaccinated mice, which efficiently neutralized SARS-CoV-2 pseudotyped virus. Moreover, the administration routes were found to affect the virus neutralizing capacity of sera derived from the immunized mice and the types (Th1-type and Th2-type) of cellular immune responses. This study indicated that liposome-based RBD-mRNA vaccine with optimal administration route might be a potential candidate against SARS-CoV-2 infection with good efficacy and safety.
科研通智能强力驱动
Strongly Powered by AbleSci AI